Assessing the impact of predictive biosimulation on drug discovery and development.
Systems biology is creating a context for interpreting the vast amounts of genomic and proteomic data being produced by pharmaceutical companies in support of drug development. While major data collection efforts capitalize on technical advances in miniaturization and automation and represent an industrialization of existing laboratory research, the transition from mental models to predictive computer simulations is setting the pace for advances in this field. This article addresses current approaches to the mathematical modeling of biological systems and assesses the potential impact of predictive biosimulation on drug discovery and development.
Michelson
Seth
S
Entelos, Inc., 110 Marsh Dr., Foster City, CA 94404, USA. michelson@entelos.com
D000818:Animals; D019295:Computational Biology; D003198:Computer Simulation; D015195:Drug Design; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008954:Models, Biological; D013598:Systems Theory